Cell-free DNA (cfDNA) analysis represents a promising method for the diagnosis, treatment
selection and clinical follow-up of cancer patients. Although its general methodological …

An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …

Improvements in genomic and molecular methods are expanding the range of potential
applications for circulating tumour DNA (ctDNA), both in a research setting and as a'liquid …

Mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival,
metabolism, and immunity. mTOR is usually assembled into several complexes such as …

Cell-free DNA fragments are shed into the bloodstream by tumor cells. The analysis of
circulating tumor DNA (ctDNA), commonly known as liquid biopsy, can be exploited for a …

Biomarkers for more precise patient care are needed in metastatic prostate cancer. We have
reported a phase II trial (TOPARP-A) of the PARP inhibitor olaparib in metastatic prostate …

New non-invasive approaches that can complement and improve on current strategies for
colorectal cancer (CRC) screening and management are urgently needed. A growing …

Cell-free DNA (cfDNA) refers to short fragments of acellular nucleic acids detectable in
almost all body fluids, including blood, and is involved in various physiological and …

Purpose: Immunotherapy has transformed the treatment of many solid tumors, with some
patients deriving long-term benefit, but how to identify such patients remains unclear …

Mutations in ESR1 have been associated with resistance to aromatase inhibitor (AI) therapy
in patients with ER+ metastatic breast cancer. Little is known of the impact of these mutations …